174 related articles for article (PubMed ID: 32886721)
41. A Novel Human Papillomavirus 16 L1 Pentamer-Loaded Hybrid Particles Vaccine System: Influence of Size on Immune Responses.
Jia C; Yang T; Liu Y; Zhu A; Yin F; Wang Y; Xu L; Wang Y; Yan M; Cai Q; Liang X; Ju R; Chen J; Wang L
ACS Appl Mater Interfaces; 2018 Oct; 10(42):35745-35759. PubMed ID: 30360122
[TBL] [Abstract][Full Text] [Related]
42. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine.
Chang EY; Chen CH; Ji H; Wang TL; Hung K; Lee BP; Huang AY; Kurman RJ; Pardoll DM; Wu T
Int J Cancer; 2000 Jun; 86(5):725-30. PubMed ID: 10797297
[TBL] [Abstract][Full Text] [Related]
43. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
[TBL] [Abstract][Full Text] [Related]
44. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.
Sewell DA; Shahabi V; Gunn GR; Pan ZK; Dominiecki ME; Paterson Y
Cancer Res; 2004 Dec; 64(24):8821-5. PubMed ID: 15604239
[TBL] [Abstract][Full Text] [Related]
45. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
[TBL] [Abstract][Full Text] [Related]
46. Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice.
Galliverti G; Tichet M; Domingos-Pereira S; Hauert S; Nardelli-Haefliger D; Swartz MA; Hanahan D; Wullschleger S
Cancer Immunol Res; 2018 Nov; 6(11):1301-1313. PubMed ID: 30131378
[TBL] [Abstract][Full Text] [Related]
47. Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells.
Choi YW; Kang MC; Seo YB; Namkoong H; Park Y; Choi DH; Suh YS; Lee SW; Sung YC; Jin HT
Clin Cancer Res; 2016 Dec; 22(23):5898-5908. PubMed ID: 27407095
[TBL] [Abstract][Full Text] [Related]
48. T-helper epitopes identified within the E6 transforming protein of cervical cancer-associated human papillomavirus type 16.
Azoury-Ziadeh R; Herd K; Fernando GJ; Frazer IH; Tindle RW
Viral Immunol; 1999; 12(4):297-312. PubMed ID: 10630789
[TBL] [Abstract][Full Text] [Related]
49. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice.
Qian J; Dong Y; Pang YY; Ibrahim R; Berzofsky JA; Schiller JT; Khleif SN
Int J Cancer; 2006 Jun; 118(12):3022-9. PubMed ID: 16425257
[TBL] [Abstract][Full Text] [Related]
50. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine].
Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710
[TBL] [Abstract][Full Text] [Related]
51. Identification of variants and therapeutic epitopes in HPV-33/HPV-58 E6 and E7 in Southwest China.
He J; Yang Y; Chen Z; Liu Y; Bao S; Zhao Y; Ding X
Virol J; 2019 May; 16(1):72. PubMed ID: 31138240
[TBL] [Abstract][Full Text] [Related]
52. GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression.
Esquerré M; Bouillette-Marussig M; Goubier A; Momot M; Gonindard C; Keller H; Navarro A; Bissery MC
PLoS One; 2017; 12(3):e0174038. PubMed ID: 28301611
[TBL] [Abstract][Full Text] [Related]
53. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
[TBL] [Abstract][Full Text] [Related]
54. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
[TBL] [Abstract][Full Text] [Related]
55. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
[TBL] [Abstract][Full Text] [Related]
56. Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T cells and protective immunity.
Kim TW; Hung CF; Kim JW; Juang J; Chen PJ; He L; Boyd DA; Wu TC
Hum Gene Ther; 2004 Feb; 15(2):167-77. PubMed ID: 14975189
[TBL] [Abstract][Full Text] [Related]
57. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.
Grasso F; Negri DR; Mochi S; Rossi A; Cesolini A; Giovannelli A; Chiantore MV; Leone P; Giorgi C; Cara A
Int J Cancer; 2013 Jan; 132(2):335-44. PubMed ID: 22700466
[TBL] [Abstract][Full Text] [Related]
58. Paucity of functional CTL epitopes in the E7 oncoprotein of cervical cancer associated human papillomavirus type 16.
Khammanivong V; Liu XS; Liu WJ; Rodda SJ; Leggatt GR; Tindle RW; Frazer IH; Fernando GJ
Immunol Cell Biol; 2003 Feb; 81(1):1-7. PubMed ID: 12534940
[TBL] [Abstract][Full Text] [Related]
59. A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.
Tang J; Yin R; Tian Y; Huang Z; Shi J; Fu X; Wang L; Wu Y; Hao F; Ni B
Vaccine; 2012 Feb; 30(6):1071-82. PubMed ID: 22178528
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic Vaccine Against Primate Papillomavirus Infections of the Cervix.
Ragonnaud E; Andersson AC; Mariya S; Pedersen AG; Burk RD; Folgori A; Colloca S; Cortese R; Nicosia A; Pamungkas J; Iskandriati D; Holst PJ
J Immunother; 2017; 40(2):51-61. PubMed ID: 28166180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]